FDA Approves Emcitate for MCT8 Deficiency: What Families Should Confirm Next

The FDA approved Emcitate (tiratricol) on September 28, 2026, as the first FDA-approved therapy for peripheral thyrotoxicosis associated with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome.
Emcitate is prepared as a liquid suspension and can be given by mouth or through an enteral feeding tube, but the dose must be individualized and adjusted using specialized total T3 testing.
Families should review current thyroid medicines, feeding instructions, monitoring plans, side effects, and country-specific access with the patient’s endocrinology team before treatment begins.

What the FDA approved on September 28, 2026

The U.S. Food and Drug Administration approved Emcitate (tiratricol) tablets for oral suspension for adults and children with MCT8 deficiency who have peripheral thyrotoxicosis. MCT8 deficiency is also called Allan-Herndon-Dudley syndrome. The FDA describes Emcitate as the first approved therapy for symptoms related to this rare genetic condition.

The approval is specifically for reducing the excess thyroid hormone activity that builds up in the bloodstream when the MCT8 transporter does not work properly. It is not a cure for the underlying genetic disorder, and the approval does not mean that every symptom or developmental effect of MCT8 deficiency will be reversed.

The FDA announcement was issued in the United States on September 28, 2026. This is a U.S. regulatory decision. It does not by itself authorize Emcitate for sale in Canada.

Why Emcitate may help with MCT8 deficiency

MCT8 is a transporter that helps thyroid hormone enter cells, including cells in the brain. In MCT8 deficiency, the faulty transporter can leave the brain with too little thyroid hormone while excess hormone remains in the circulation. That combination can affect development, movement, speech, feeding, heart function, and metabolism.

Tiratricol is designed to act without relying on the MCT8 transporter. By entering cells through a different route, it can activate thyroid hormone receptors and reduce circulating T3 levels. The FDA reviewed evidence from two studies, including a randomized placebo-controlled withdrawal study and a longer-term open-label study. Across those studies, treated patients had reductions in excess thyroid hormone levels, along with improvements in measures affected by thyroid hormone excess, including heart rate and systolic blood pressure.

Those findings are meaningful, but families should keep the scope of the approval in mind: Emcitate treats peripheral thyrotoxicosis associated with MCT8 deficiency. It should not be described as a general treatment for developmental disability, muscle weakness, feeding problems, or other features unless a specialist explains what improvement might reasonably be expected for an individual patient.

How Emcitate is given

Emcitate is supplied as a 350-microgram tablet for oral suspension. The tablet must be dispersed in room-temperature drinking water before it is given. It should not be swallowed whole, chewed, or crushed.

The prepared suspension may be administered by mouth or directly into the stomach through an enteral feeding tube. That option may be particularly relevant for children and adults who have difficulty swallowing. The prescribing information includes separate preparation and administration instructions, so caregivers should ask the prescribing team or pharmacist to demonstrate the process rather than relying on a general description.

The total daily dose is individualized according to body weight, total T3 levels, and signs or symptoms of thyrotoxicosis. The label allows the daily dose to be given once daily or divided into two or three doses across the day. The starting dose depends on weight, and the dose may be increased gradually during treatment.

What to confirm	Why it matters
Starting and maximum dose	The dose is based on weight, laboratory results, and symptoms rather than a single standard amount.
Preparation method	The tablet must be dispersed in room-temperature water and must not be swallowed whole.
Feeding-tube instructions	The care team should confirm the correct tube route, flushing instructions, and timing around other medicines.
Dose schedule	The prescription may use one daily dose or divided doses, depending on the patient’s plan.

Four issues families should discuss before starting

1. Existing thyroid medicines

The FDA label says Emcitate is not recommended with other thyroid medications. The warning includes medicines such as levothyroxine, propylthiouracil, and carbimazole because combining thyroid-directed products may increase the risk of excessive thyroid activity or hypothyroidism.

Do not stop or change an existing prescription on your own. Instead, give the endocrinology team a complete list of prescription medicines, over-the-counter products, vitamins, and supplements. The specialist should explain whether any current thyroid treatment needs to be stopped, changed, or monitored differently before Emcitate begins.

2. The type of T3 test being used

Emcitate can interfere with some T3 immunoassays and make the result appear higher than it really is. The prescribing information recommends measuring total T3 with liquid chromatography-tandem mass spectrometry, commonly called LC-MS/MS.

The label also notes that an FDA-authorized LC-MS/MS test for total T3 is not currently available and that available LC-MS/MS methods may vary in accuracy. This makes it important for the treating team to identify the laboratory method before treatment and to use a consistent, clinically appropriate monitoring plan.

Families can ask which laboratory will perform the test, how often testing is expected during dose adjustment, and how symptoms will be considered alongside the laboratory result.

3. Symptoms during dose adjustment

Signs of excessive thyroid activity can occur when treatment starts or while the dose is being increased. The label lists increased heart rate, elevated blood pressure, diarrhea, excessive sweating, irritability, insomnia, and nightmares among the symptoms that may need attention.

The most common reported adverse reactions were diarrhea, vomiting, rash, and excessive sweating. In the longer-term study, some participants also experienced temporary increases in heart rate or systolic blood pressure during dose titration.

Ask the care team which symptoms require a same-day call, which require urgent medical attention, and how to handle vomiting or a missed dose. The prescribing information has specific instructions for these situations, but the patient’s clinician should explain how they apply to the individual prescription.

4. Other medicines and supplements

In addition to other thyroid medicines, several products may affect Emcitate’s absorption or response. The label identifies possible concerns with iron and calcium supplements, bile acid sequestrants, ion-exchange resins, proton pump inhibitors, oral anticoagulants, and psychostimulants.

This does not mean every patient must avoid all of these products. It means the medication list needs to be reviewed before treatment and whenever another medicine is started, stopped, or changed. Caregivers should also ask whether vitamins, nutrition products, or tube-feeding schedules need to be separated from Emcitate.

What the approval means in the United States and Canada

United States

In the United States, Emcitate now has FDA approval for the indicated use in adults and pediatric patients with MCT8 deficiency and peripheral thyrotoxicosis. The approval was granted to Egetis Therapeutics US Inc. The FDA-approved prescribing information is the best source for the formal indication, dosage framework, warnings, interactions, and administration instructions.

FDA approval does not guarantee that a prescription will be immediately available at every pharmacy or that every insurance plan will cover it. Families should ask the specialist’s office and pharmacist about the current dispensing route, prior authorization requirements, specialty-pharmacy arrangements, and any manufacturer assistance that may apply.

Read the FDA-approved Emcitate prescribing information

Canada

The September 28 FDA announcement is not a Health Canada approval. Canadian families should not assume that an FDA-approved prescription can automatically be marketed, dispensed, or reimbursed in Canada.

Ask the treating physician or pharmacist whether Emcitate has a Canadian authorization, whether a submission or review has been announced, and what lawful access options may exist if it is not authorized for sale. Health Canada’s Drug Product Database and Notice of Compliance Database are the appropriate official places to check Canadian authorization information, but a specialist should help interpret the result for a rare-disease treatment.

A practical appointment checklist

Confirm that the diagnosis and the treatment indication match MCT8 deficiency with peripheral thyrotoxicosis.
Bring a complete medication and supplement list, including thyroid medicines, iron, calcium, antacids, and tube-feeding products.
Ask the team to demonstrate how to disperse the tablet and administer the suspension by mouth or feeding tube.
Confirm the laboratory method for total T3 testing and the planned schedule for follow-up tests.
Ask how heart rate, blood pressure, symptoms, and dose changes will be monitored.
Get written instructions for vomiting, a missed dose, worsening symptoms, and urgent warning signs.
For Canadian patients, confirm the current regulatory and access pathway in Canada rather than relying only on the U.S. approval.

As of October 1, 2026, the FDA approval is confirmed, but treatment decisions, access arrangements, and monitoring plans still need to be handled case by case by a clinician familiar with MCT8 deficiency.

Helpful Links

FDA approval announcement for Emcitate – Read the FDA's September 28, 2026 announcement describing the approval, study findings, administration route, and common side effects.
FDA-approved Emcitate prescribing information – Review the official indication, dosing framework, preparation instructions, laboratory testing warning, interactions, and patient counseling information.
Health Canada Drug Product Database – Search for drugs authorized for sale in Canada and review Canadian product information when available.
Health Canada Notice of Compliance Database – Check Canadian regulatory compliance records for authorized new drugs and related products.

Frequently Asked Questions

Q. Is Emcitate a cure for MCT8 deficiency?

A. No. Emcitate is approved to treat peripheral thyrotoxicosis associated with MCT8 deficiency. It addresses excess thyroid hormone activity in the bloodstream, but it does not correct the underlying genetic transporter problem or guarantee reversal of developmental or neurologic effects.

Q. Can Emcitate be given through a feeding tube?

A. Yes. The FDA-approved label allows the prepared liquid suspension to be administered orally or through an enteral feeding tube. The tablet must first be dispersed in room-temperature drinking water and should not be swallowed whole, chewed, or crushed.

Q. Why does the Emcitate label call for a special T3 test?

A. Tiratricol can interfere with some T3 immunoassays and produce unreliable or falsely elevated results. The label recommends measuring total T3 with an LC-MS/MS method, while also noting that available methods may vary in accuracy.

Q. Can a patient take Emcitate with levothyroxine or another thyroid medicine?

A. The FDA label says Emcitate is not recommended with other thyroid medications, including examples such as levothyroxine, propylthiouracil, and carbimazole. The prescribing clinician must decide how existing treatment should be changed; families should not make that change without medical guidance.

Q. Does the FDA approval mean Emcitate is available in Canada?

A. Not automatically. The FDA approval applies to the United States. Canadian families should confirm Canadian authorization, availability, and any access pathway with a specialist or pharmacist and through Health Canada’s official drug databases.